中山大学孙逸仙纪念医院
逸仙优秀青年医学人才
培养计划
作者:人力资源部   发布时间:2019-11-08 点击数:135
<< 更多 >>
刘洁琼

基本情况

姓名:刘洁琼

性别:
职称:副主任医师

行政职务

学科专业:乳腺外科

导师资格:硕士生导师

研究方向:乳腺癌及良性疾病的外科手术,乳腺癌的新辅助治疗及免疫联合抗血管生成治疗。

电子邮箱:liujieqiong01@163.com

 

 

个人简介

 

硕士生导师,中华医学会肿瘤分会乳腺肿瘤学组青委,中国康复医学会修复重建外科专委会委员,哈佛大学麻省总医院联合培养博士,约翰霍普金斯医院博士后

具体研究方向:乳腺癌的外科手术,新辅助治疗及免疫治疗

广东省杰出青年医学人才, CSCO35under35”最具潜力青年医师,逸仙优秀人才

 

 

重要学术研究成果与贡献

一、主持科研项目

1.国家自然科学基金、阻断肿瘤微环境中TGF-β增强三阴乳腺癌脑转移瘤放疗敏感性及其机制研究、2017/01-2019/12排名第一

2.广东省自然科学基金、阻断肿瘤微环境中TGF-β对三阴乳腺癌脑转移瘤生长和放疗敏感性的影响及机制研究、2015/01-2018/01排名第一

3.中山大学5010培育基金、ER阳性、HER2阴性绝经后可手术乳腺癌依维莫司联合来曲唑对比FEC新辅助化疗疗效比较前期研究、2016/01-2018/01排名第一

4.中山大学孙逸仙纪念医院逸仙临床研究培育基金、可手术三阴乳腺癌节拍对比常规新辅助化疗疗效比较随机对照临床研究、2017/01-2020/01排名第一

5.中山大学孙逸仙纪念医院逸仙优秀人才基金、多西他赛联合卡培他滨+环磷酰胺节拍化疗序贯FEC对比常规新辅助化疗治疗可手术三阴乳腺癌随机对照临床研究、2017/07-2020/07排名第一

二、代表性论著

[1]     Jieqiong Liu, Shan liao, Ben Diop-Frimpong, Wei Chen, ShomGoel, Kamila Naxerova, M Ancukiewicz, Yves Boucher, Rakesh K. Jain*, Lei Xu*. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16618-23.

[2]     Jieqiong Liu, Shan liao, Yuhui Huang, Rekha Samuel, Tony Shi, Peigen Huang, WalidKamoun, Kamila Naxerova, Rakesh K. Jain, Dai Fukumura, Lei Xu*. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 2011 Jun 1;17(11):3638-48.

[3]     Yaping Yang, Ying Wang, Heran Deng, Cui Tan, Qian Li, Zhanghai He, Wei Wei,

Enxiang Zhou, Qiang Liu*, and Jieqiong Liu*(共同通讯).Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer. BMC Cancer 2019 Jun 6;19(1):541.

[4]     Dajiang Song, Dequan Liu, Georgios Pafitanis, Zeyang Liu, Xi Wang, Xiao Zhou,

Jieqiong Liu*(共同通讯),Zan Li *. Extensive Microsurgical Reconstruction of Chest Wall Defects for Locally Advanced Breast Cancer: A 10-Year Single-Unit Experience.Ann Plast Surg. 2019 Jul 19.

[5]     Kai Mao,Yongcong Yan, Jianlong Zhang, Jie Wang, Ruomei Wang, Wan-Yee Lau,

Shuai Jiang,Jieqiong Liu*(共同通讯),Zhiyu Xiao*. The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: A propensity score matching study.Cancer Medicine 201874475-4484

[6]     Jieqiong Liu#*, Kai Chen#, Wen Jiang, Kai Mao, Shunrong Li, Min Ji Kim, Qiang

Liu, Lisa K. Jacobs*. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. J Cancer Res Clin Oncol 2017 Jan;143(1):161-168.

[7]     Wei Wu#, Heran Deng#, Nanyan Rao, Na You, Yaping Yang, Minghui Cao*,

Jieqiong Liu*, Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. Trials. 2017 Oct 25;18(1):497. doi: 10.1186/s13063-017-2228-5

[8]     Kai Mao, Yaping Yang, Wei Wu, Shi Liang, Heran Deng, Jieqiong Liu*.Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status. Plos One2017 May 3;12(5):e0176417.

[9]     Kai Chen#,*, Jieqiong Liu#(共同第一), Shunrong Li#, Lisa Jacobs*. Development of nomograms to predict axillary lymph node status in breast cancer patients.BMC Cancer. 2017 Aug 23;17(1):561.

[10]  Mingxia Zhang#, Jiannan Wu#, Kai Mao, Heran Deng, Yaping Yang, Enxiang Zhou, Jieqiong Liu*. Role of transforming growth factor-β1 in triple negative breast cancer patients.Int J Surg. 2017 Jul 25;45:72-76. doi: 10.1016/j.ijsu.2017.07.080.

[11]  Jieqiong Liu#,*(共同第一&共同通讯), Kai Mao#, Shuai Jiang, Wen Jiang, Kai Chen, Betty Kim, Qiang Liu, Lisa K. Jacobs*. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB.Oncotarget, 2016 Apr 26;7(17):24848-59.

[12]  Jieqiong Liu#,*(共同第一&共同通讯), Kai Chen#, Kai Mao, FengxiSu,Qiang Liu, Lisa K. Jacobs*. The prognostic value of age for invasive lobular breast cancer depending on estrogen receptor and progesterone receptor-defined subtypes: A NCDB analysis.Oncotarget, 2016 Feb 2;7(5):6063-73.

[13]  Kai Chen#, Jieqiong Liu#(共同第一),Liling Zhu, FengxiSu,Erwei Song , Lisa K. Jacobs*. Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: A NCDB analysis.Oncotarget, 2015 Nov 24;6(37):40127-40.

[14]  Jieqiong Liu# (共同第一), Huishan Guo#, Kai Mao, Kan Zhang, Heran Deng, Qiang Liu*. Impact of estrogen receptor-β expression on breast cancer prognosis: a meta-analysis.Breast Cancer Res Treat2016 Feb;156(1):149-62.

[15]  Jieqiong Liu, Wen Jiang, Kai Mao, Yi An, FengxiSu, Betty Y.S. Kim, Qiang Liu*, Lisa K. Jacobs*. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat, 2015 Apr;150(2):439-45.

[16]  Jianli Zhao#, Jieqiong Liu#(共同第一), Kai Chen#, Shunrong Li, Ying Wang, Yaping Yang, Qiang Liu, FengxiSu*. What lies behind chemotherapy-induced amenorrhea for breast cancer patientsA meta-analysis. Breast Cancer Res Treat 2014 May;145(1):113-28.

[17]  Shunrong Li#, Jieqiong Liu#(共同第一), Yaping Yang, Yunjie Zeng, Heran Deng, Haixia Jia, Qian Li, Huiyi Feng, Yangyang Li, Erwei Song, Qiang Liu*, FengxiSu*. Impact of atypical hyperplasia at margins of breast-conserving surgery on the recurrence of breast cancer.J Cancer Res Clin Oncol. 2014 Apr;140(4):599-605.

[18]  Jieqiong Liu, Heran Deng, WeijuanJia, Yunjie Zeng, Nanyan Rao, Shunrong Li, Liang Jin, Erwei Song*, FengxiSu*. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breastcarcinoma in patients with or without treatment. J Cancer Res ClinOncol2012 May;138(5):837-42.

[19]  Kai Mao#, Jieqiong Liu# (共同第一), Jian Sun, Jianlong Zhang, Jie Chen, Timothy Pawlik, Lisa Jacobs, Zhiyu Xiao, Jie Wang, Patterns and Prognostic Value of Lymph Node Dissection for Resected perihilarcholangiocarcinoma. J GastroenterolHepatol, 2016 Feb;31(2):417-26.

[20]  Yaping Yang#, Jieqiong Liu# (共同第一), Ran Gu, Yue Hu, Fengtao Liu, Mei Wu, Qiang Liu,FengxiSu. Influence of factors on mammographic density in premenopausal Chinese women. Eur J Cancer Prev2016 Jul;25(4):306-11.

[21]  Jieqiong Liu, WeijuanJia, Yunjie Zeng, Heran Deng, Nanyan Rao, FengxiSu. Adolescent male adenoid cystic breast carcinoma. Am Surg. 2012 May;78(5):E288-9.

[22]  Kai Mao, Wen Jiang, Jieqiong Liu*(共同通讯), Jie Wang*. Incidence ofsubsequent cholangiocarcinomas after another malignancy: trends in a population-based study. Medicine (Baltimore). 2015 Feb;94(8):e596.

 

学术论著与教材

1)Jieqiong Liu, Lisa K. Jacobs*.Current Surgical Therapy 12th editionChapter: “The Management of Benign Breast Disease”. Elsevier, 2017.1.

2)Fengyan Yu, Qiang Liu, Yujie Liu, Jieqiong Liu, Erwei Song*. Breast Cancer - Focusing Tumor Microenvironment, Stem cells and MetastasisChapter:“Breast Cancer Stem Cells”. Intech2012. 12.

3)刘洁琼,宋尔卫。《乳腺癌靶向治疗原则与实践》,“人表皮生长因子受体信号通路”、“VEGF络氨酸激酶信号传递途径”两章节。人民卫生出版社,2015.05

4刘洁琼等。《乳腺癌保乳治疗》,“早期乳腺癌术式选择的影响因素”、“局部复发的重要性”、“新辅助化疗降期后的保乳问题”、“局部晚期乳癌新辅助化疗后的保乳”、“多学科会诊与保乳手术”五章节。人民卫生出版社,2014.08

 

获奖及荣誉

广东省杰出青年医学人才,CSCO35under35”最具潜力青年医师,逸仙优秀人才

学术兼职

1.中华医学会肿瘤分会乳腺学组青年委员

2.中国抗癌协会中西医整合肿瘤专委会青年常委

3.中国康复医学会修复重建外科专委会体表肿瘤学组委员

4.广东省预防医学会流行病学专业委员会青年常委

5.广东省胸部疾病学会乳腺病防治学组常委

 

相关文章